Global Oral hypoglycemic agents and insulin analogues Market Research Report 2017-2022 by Players, Regions, Product Types & Applications

July 2017 | 125 pages | ID: GF0AB1284BBEN
DataMarketResearch (DMR)

Abstracts

The global Oral hypoglycemic agents and insulin analogues market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

This report offers an overview of the market trends, drivers, and barriers with respect to the Oral hypoglycemic agents and insulin analogues market. It also provides a detailed overview of the market of different regions across United States, Europe, China, Japan, India, Southeast Asia and Others. The report categorizes Oral hypoglycemic agents and insulin analogues market by by Insulin sensitizing agents, by Secretagogue, by Insulin class, by Others, and application. Detailed analysis of key players, along with key growth strategies adopted by them is also covered in this report on Oral hypoglycemic agents and insulin analogues market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

This report focuses Global market, it covers details as following:

Key Players

• ASTRAZENECA AB
• AUROBINDO PHARMA LTD
• BAYER HLTHCARE
• BOEHRINGER INGELHEIM
• CIPLA LTD
• DR REDDYS LABS LTD
• EPIC PHARMA LLC
• HERITAGE PHARMS INC
• IMPAX LABS
• INVAGEN PHARMS
• JANSSEN PHARMS
• LABS LLC
• LUPIN LTD
• MACLEODS PHARMS LTD
• MANNKIND
• MERCK SHARP DOHME
• MICRO LABS LTD INDIA
• MYLAN
• NOVO NORDISK INC
• PADDOCK LLC
• PAR PHARM
• PFIZER
• SANDOZ
• SANOFI AVENTIS US
• SANTARUS INC
• SB PHARMCO
• SUN PHARM INDS INC
• TAKEDA PHARMS USA
• TEVA
• APOTEX

Key Regions

• North America
• United States
• Canada
• Latin America
• Mexico
• Brazil
• Argentina
• Others
• Europe
• Germany
• United Kingdom
• France
• Italy
• Spain
• Russia
• Netherland
• Others
• Asia & Pacific
• China
• Japan
• India
• Korea
• Australia
• Southeast Asia
• Indonesia
• Thailand
• Philippines
• Vietnam
• Singapore
• Malaysia
• Others
• Africa & Middle East
• South Africa
• Egypt
• Turkey
• Saudi Arabia
• Iran
• Others

Main types of products

Oral hypoglycemic agents and insulin analogues Market, by Insulin sensitizing agents

• Metformin
• Buformin
• Phenformin
• Pioglitazone
• Rosiglitazone
• Troglitazone
• Aleglitazar
• Muraglitazar
• Tesaglitazar

Oral hypoglycemic agents and insulin analogues Market, by Secretagogue

• Acetohexamide
• Carbutamide
• Chlorpropamide
• Metahexamide
• Tolazamide
• Tolbutamide
• Glibenclamide
• Glibornuride
• Glipizide
• Gliquidone
• Glisoxepide
• Glyclopyramide
• Glimepiride
• Gliclazide
• Nateglinide
• Repaglinide
• Mitiglinide
• Exenatide
• Liraglutide
• Lixisenatide
• Linagliptin
• Saxagliptin
• Sitagliptin
• Vildagliptin

Oral hypoglycemic agents and insulin analogues Market, by Insulin class

• Insulin Lispro
• Insulin aspart
• Glulisine
• insulin
• insulin glargine
• insulin detemir
• neutral protamine Hagedorn insulin

Oral hypoglycemic agents and insulin analogues Market, by Others

• Acarbose
• Miglitol
• Voglibose
• Pramlintide
• Benfluorex
• Tolrestat

Oral hypoglycemic agents and insulin analogues Market, by Key Consumer

• Department of endocrinology
• Diabetes division
• Pharmacy
• Hospital

Contents

CHAPTER ONE METHODOLOGY AND DATA SOURCE

1.1 Methodology/Research Approach
  1.1.1 Research Programs/Design
  1.1.2 Market Size Estimation
  1.1.3 Market Breakdown and Data Triangulation
1.2 Data Source
  1.2.1 Secondary Sources
  1.2.2 Primary Sources
1.3 Disclaimer

CHAPTER TWO ORAL HYPOGLYCEMIC AGENTS AND INSULIN ANALOGUES MARKET OVERVIEW

2.1 Market Coverage
2.2 Global Oral hypoglycemic agents and insulin analogues Market Sales Volume Revenue and Price 2012-2017

CHAPTER THREE ORAL HYPOGLYCEMIC AGENTS AND INSULIN ANALOGUES BY KEY PLAYERS 2012-2017

3.1 Global Oral hypoglycemic agents and insulin analogues Sales Volume Market Share by Key Players 2012-2017
3.2 Global Oral hypoglycemic agents and insulin analogues Revenue Share by Key Players 2012-2017
3.3 Global Key Players Oral hypoglycemic agents and insulin analogues Key Product Model and Market Performance
3.4 Global Key Players Oral hypoglycemic agents and insulin analogues Key Target Consumers and Market Performance

CHAPTER FOUR ORAL HYPOGLYCEMIC AGENTS AND INSULIN ANALOGUES BY REGIONS 2012-2017

4.1 Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Regions 2012-2017
4.2 Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Regions 2012-2017
4.3 Global Oral hypoglycemic agents and insulin analogues Price by Regions 2012-2017
4.4 North America
  4.4.1 United States
  4.4.2 Canada
4.5 Latin America
  4.5.1 Mexico
  4.5.2 Brazil
  4.5.3 Argentina
  4.5.4 Others in Latin America
4.6 Europe
  4.6.1 Germany
  4.6.2 United Kingdom
  4.6.3 France
  4.6.4 Italy
  4.6.5 Spain
  4.6.6 Russia
  4.6.7 Netherland
  4.6.8 Others in Europe
4.7 Asia & Pacific
  4.7.1 China
  4.7.2 Japan
  4.7.3 India
  4.7.4 Korea
  4.7.5 Australia
  4.7.6 Southeast Asia
    4.7.6.1 Indonesia
    4.7.6.2 Thailand
    4.7.6.3 Philippines
    4.7.6.4 Vietnam
    4.7.6.5 Singapore
    4.7.6.6 Malaysia
    4.7.6.7 Others in Southeast Asia
4.8 Africa & Middle East
  4.8.1 South Africa
  4.8.2 Egypt
  4.8.3 Turkey
  4.8.4 Saudi Arabia
  4.8.5 Iran
  4.8.6 Others in Africa & Middle East

CHAPTER FIVE ORAL HYPOGLYCEMIC AGENTS AND INSULIN ANALOGUES MARKET BY PRODUCT TYPES

5.1 Oral hypoglycemic agents and insulin analogues, by Insulin sensitizing agents 2012-2017
  5.1.1 Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Insulin sensitizing agents 2012-2017
  5.1.2 Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Insulin sensitizing agents 2012-2017
  5.1.3 Global Oral hypoglycemic agents and insulin analogues Price by Insulin sensitizing agents 2012-2017
  5.1.4 Metformin
  5.1.5 Buformin
  5.1.6 Phenformin
  5.1.7 Pioglitazone
  5.1.8 Rosiglitazone
  1.2.8 Tolazamide
  1.2.9 Troglitazone
  1.2.10 Aleglitazar
  1.2.11 Muraglitazar
  1.2.12 Tesaglitazar
5.2 Oral hypoglycemic agents and insulin analogues, by Secretagogue 2012-2017
  5.2.1 Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Secretagogue 2012-2017
  5.2.2 Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Secretagogue 2012-2017
  5.2.3 Global Oral hypoglycemic agents and insulin analogues Price by Secretagogue 2012-2017
  5.2.4 Acetohexamide
  5.2.5 Carbutamide
  5.2.6 Chlorpropamide
  5.2.7 Metahexamide
  5.2.8 Tolazamide
  1.3.9 Tolbutamide
  1.3.10 Glibenclamide
  1.3.11 Glibornuride
  1.3.12 Glipizide
  1.3.13 Gliquidone
  1.3.14 Glisoxepide
  1.3.15 Glyclopyramide
  1.3.16 Glimepiride
  1.3.17 Gliclazide
  1.3.18 Nateglinide
  1.3.19 Repaglinide
  1.3.20 Mitiglinide
  1.3.21 Exenatide
  1.3.22 Liraglutide
  1.3.23 Lixisenatide
  1.3.24 Linagliptin
  1.3.25 Saxagliptin
  1.3.26 Sitagliptin
  1.2.37 Vildagliptin
5.3 Oral hypoglycemic agents and insulin analogues, by Insulin class 2012-2017
  5.3.1 Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Insulin class 2012-2017
  5.3.2 Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Insulin class 2012-2017
  5.3.3 Global Oral hypoglycemic agents and insulin analogues Price by Insulin class 2012-2017
  5.3.4 Insulin Lispro
  5.3.5 Insulin aspart
  5.3.6 Glulisine
  5.3.7 insulin
  5.3.8 insulin glargine
  1.4.9 neutral protamine Hagedorn insulin
5.4 Oral hypoglycemic agents and insulin analogues, by Others 2012-2017
  5.4.1 Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Others 2012-2017
  5.4.2 Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Others 2012-2017
  5.4.3 Global Oral hypoglycemic agents and insulin analogues Price by Others 2012-2017
  5.4.4 Acarbose
  5.4.5 Miglitol
  5.4.6 Voglibose
  5.4.7 Pramlintide
  5.4.8 Benfluorex
  1.5.9 Tolrestat

CHAPTER SIX GLOBAL KEY PLAYERS PROFILE

6.1 ASTRAZENECA AB
  6.1.1 ASTRAZENECA AB Company Details and Competitors
  6.1.2 ASTRAZENECA AB Key Oral hypoglycemic agents and insulin analogues Models and Performance
  6.1.3 ASTRAZENECA AB Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast
  6.1.4 ASTRAZENECA AB Oral hypoglycemic agents and insulin analogues Sales Volume Revenue Price Cost and Gross Margin
6.2 AUROBINDO PHARMA LTD
  6.2.1 AUROBINDO PHARMA LTD Company Details and Competitors
  6.2.2 AUROBINDO PHARMA LTD Key Oral hypoglycemic agents and insulin analogues Models and Performance
  6.2.3 AUROBINDO PHARMA LTD Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast
  6.2.4 AUROBINDO PHARMA LTD Oral hypoglycemic agents and insulin analogues Sales Volume Revenue Price Cost and Gross Margin
6.3 BAYER HLTHCARE
  6.3.1 BAYER HLTHCARE Company Details and Competitors
  6.3.2 BAYER HLTHCARE Key Oral hypoglycemic agents and insulin analogues Models and Performance
  6.3.3 BAYER HLTHCARE Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast
  6.3.4 BAYER HLTHCARE Oral hypoglycemic agents and insulin analogues Sales Volume Revenue Price Cost and Gross Margin
6.4 BOEHRINGER INGELHEIM
  6.4.1 BOEHRINGER INGELHEIM Company Details and Competitors
  6.4.2 BOEHRINGER INGELHEIM Key Oral hypoglycemic agents and insulin analogues Models and Performance
  6.4.3 BOEHRINGER INGELHEIM Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast
  6.4.4 BOEHRINGER INGELHEIM Oral hypoglycemic agents and insulin analogues Sales Volume Revenue Price Cost and Gross Margin
6.5 CIPLA LTD
  6.5.1 CIPLA LTD Company Details and Competitors
  6.5.2 CIPLA LTD Key Oral hypoglycemic agents and insulin analogues Models and Performance
  6.5.3 CIPLA LTD Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast
  6.5.4 CIPLA LTD Oral hypoglycemic agents and insulin analogues Sales Volume Revenue Price Cost and Gross Margin
6.6 DR REDDYS LABS LTD
  6.6.1 DR REDDYS LABS LTD Company Details and Competitors
  6.6.2 DR REDDYS LABS LTD Key Oral hypoglycemic agents and insulin analogues Models and Performance
  6.6.3 DR REDDYS LABS LTD Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast
  6.6.4 DR REDDYS LABS LTD Oral hypoglycemic agents and insulin analogues Sales Volume Revenue Price Cost and Gross Margin
6.7 EPIC PHARMA LLC
  6.7.1 EPIC PHARMA LLC Company Details and Competitors
  6.7.2 EPIC PHARMA LLC Key Oral hypoglycemic agents and insulin analogues Models and Performance
  6.7.3 EPIC PHARMA LLC Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast
  6.7.4 EPIC PHARMA LLC Oral hypoglycemic agents and insulin analogues Sales Volume Revenue Price Cost and Gross Margin
6.8 HERITAGE PHARMS INC
  6.8.1 HERITAGE PHARMS INC Company Details and Competitors
  6.8.2 HERITAGE PHARMS INC Key Oral hypoglycemic agents and insulin analogues Models and Performance
  6.8.3 HERITAGE PHARMS INC Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast
  6.8.4 HERITAGE PHARMS INC Oral hypoglycemic agents and insulin analogues Sales Volume Revenue Price Cost and Gross Margin
6.9 IMPAX LABS
  6.9.1 IMPAX LABS Company Details and Competitors
  6.9.2 IMPAX LABS Key Oral hypoglycemic agents and insulin analogues Models and Performance
  6.9.3 IMPAX LABS Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast
  6.9.4 IMPAX LABS Oral hypoglycemic agents and insulin analogues Sales Volume Revenue Price Cost and Gross Margin
6.10 INVAGEN PHARMS
  6.10.1 INVAGEN PHARMS Company Details and Competitors
  6.10.2 INVAGEN PHARMS Key Oral hypoglycemic agents and insulin analogues Models and Performance
  6.10.3 INVAGEN PHARMS Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast
  6.10.4 INVAGEN PHARMS Oral hypoglycemic agents and insulin analogues Sales Volume Revenue Price Cost and Gross Margin
6.11 JANSSEN PHARMS
6.12 LABS LLC
6.13 LUPIN LTD
6.14 MACLEODS PHARMS LTD
6.15 MANNKIND
6.16 MERCK SHARP DOHME
6.17 MICRO LABS LTD INDIA
6.18 MYLAN
6.19 NOVO NORDISK INC
6.20 PADDOCK LLC
6.21 PAR PHARM
6.22 PFIZER
6.23 SANDOZ
6.24 SANOFI AVENTIS US
6.25 SANTARUS INC
6.26 SB PHARMCO
6.27 SUN PHARM INDS INC
6.28 TAKEDA PHARMS USA
6.29 TEVA
6.30 APOTEX

CHAPTER SEVEN ORAL HYPOGLYCEMIC AGENTS AND INSULIN ANALOGUES BY APPLIANCE 2012-2017

7.1 Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Appliance 2012-2017
7.2 Department of endocrinology
7.3 Diabetes division
7.4 Pharmacy
7.5 Hospital
7.6 Consuming Habit and Preference

CHAPTER EIGHT INDUSTRY CHAIN AND SUPPLY CHAIN

8.1 Oral hypoglycemic agents and insulin analogues Industry Chain Structure
  8.1.1 R&D
  8.1.2 Raw Materials (Components)
  8.1.3 Manufacturing Plants
  8.1.4 Regional Trading (Import Export and Local Sales)
  8.1.5 Online Sales Channel
  8.1.6 Offline Channel
  8.1.7 End Users
8.2 Oral hypoglycemic agents and insulin analogues Manufacturing
  8.2.1 Key Components
  8.2.2 Assembly Manufacturing
8.3 Consumer Preference
8.4 Behavioral Habits
8.5 Marketing Environment

CHAPTER NINE GLOBAL ORAL HYPOGLYCEMIC AGENTS AND INSULIN ANALOGUES MARKET SIZE (SALES AND REVENUE) FORECAST (2017-2022)

9.1 Global Oral hypoglycemic agents and insulin analogues Sales (), Revenue (Million USD) Forecast (2017-2022)
9.2 Global Oral hypoglycemic agents and insulin analogues Sales () Forecast by Regions (2017-2022)
9.3 Global Oral hypoglycemic agents and insulin analogues Sales () Forecast by Application (2017-2022)
9.4 Global Oral hypoglycemic agents and insulin analogues Sales () Forecast by Insulin sensitizing agents (2017-2022)
9.5 Global Oral hypoglycemic agents and insulin analogues Sales () Forecast by Secretagogue (2017-2022)
9.6 Global Oral hypoglycemic agents and insulin analogues Sales () Forecast by Insulin class (2017-2022)
9.7 Global Oral hypoglycemic agents and insulin analogues Sales () Forecast by Others (2017-2022)

CHAPTER TEN DEVELOPMENT TREND AND RESEARCH CONCLUSION

10.1 Development Trend
10.2 Research Conclusion

List Of Tables

LIST OF TABLES AND FIGURES

Table Global Oral hypoglycemic agents and insulin analogues Sales Volume (), Revenue (Million USD) and Price ()(2012-2017)
Figure Global Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Growth Rate (2012-2017)
Figure Global Oral hypoglycemic agents and insulin analogues Sales Volume () and Growth Rate (2012-2017)
Table Global Oral hypoglycemic agents and insulin analogues Sales Volume () by Key Players (2012-2017)
Table Global Oral hypoglycemic agents and insulin analogues Sales Volume Market Share by Key Players (2012-2017)
Figure Global Oral hypoglycemic agents and insulin analogues Sales Volume Market Share by Key Players 2016
Figure Global Oral hypoglycemic agents and insulin analogues Sales Volume Market Share by Key Players 2017
Table Global Oral hypoglycemic agents and insulin analogues Revenue (Million USD) by Key Players (2012-2017)
Table Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Key Players (2012-2017)
Figure Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Key Players 2016
Figure Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Key Players 2017
Table Global Key Players Key Product Model and Market Performance
Table Global Key Players Key Target Consumers and Market Performance
Table Global Oral hypoglycemic agents and insulin analogues Sales () by Regions (2012-2017)
Table Global Oral hypoglycemic agents and insulin analogues Sales Share by Regions (2012-2017)
Figure Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Regions in 2016
Figure Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Regions in 2017
Table Global Oral hypoglycemic agents and insulin analogues Revenue (Million USD) by Regions (2012-2017)
Table Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Regions (2012-2017)
Figure Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Regions in 2016
Figure Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Regions in 2017
Table Global Oral hypoglycemic agents and insulin analogues Price () by Regions (2012-2017)
Table North America Oral hypoglycemic agents and insulin analogues Sales () by Regions (2012-2017)
Table North America Oral hypoglycemic agents and insulin analogues Revenue (Million USD) by Regions (2012-2017)
Table North America Oral hypoglycemic agents and insulin analogues Sales Volume () by Key Players 2012-2017
Figure North America Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)
Table Latin America Oral hypoglycemic agents and insulin analogues Sales () by Regions (2012-2017)
Table Latin America Oral hypoglycemic agents and insulin analogues Revenue (Million USD) by Regions (2012-2017)
Table Latin America Oral hypoglycemic agents and insulin analogues Sales Volume () by Key Players (2012-2017)
Figure Latin America Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)
Table Europe Oral hypoglycemic agents and insulin analogues Sales () by Regions (2012-2017)
Table Europe Oral hypoglycemic agents and insulin analogues Revenue (Million USD) by Regions (2012-2017)
Table Europe Oral hypoglycemic agents and insulin analogues Sales Volume () by Key Players (2012-2017)
Figure Europe Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)
Table Asia & Pacific Oral hypoglycemic agents and insulin analogues Sales () by Regions (2012-2017)
Table Asia & Pacific Oral hypoglycemic agents and insulin analogues Revenue (Million USD) by Regions (2012-2017)
Table Asia & Pacific Oral hypoglycemic agents and insulin analogues Sales Volume () by Key Players (2012-2017)
Figure Asia & Pacific Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)
Table Africa & Middle East Oral hypoglycemic agents and insulin analogues Sales () by Regions (2012-2017)
Table Africa & Middle East Oral hypoglycemic agents and insulin analogues Revenue (Million USD) by Regions (2012-2017)
Table Africa & Middle East Oral hypoglycemic agents and insulin analogues Sales Volume () by Key Players (2012-2017)
Figure Africa & Middle East Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)
Table Global Oral hypoglycemic agents and insulin analogues Sales () by Insulin sensitizing agents (2012-2017)
Table Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Insulin sensitizing agents (2012-2017)
Figure Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Insulin sensitizing agents in 2016
Table Global Oral hypoglycemic agents and insulin analogues Revenue (Million USD) by Insulin sensitizing agents (2012-2017)
Table Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Insulin sensitizing agents (2012-2017)
Figure Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Insulin sensitizing agents in 2016
Table Global Oral hypoglycemic agents and insulin analogues Price () by Insulin sensitizing agents (2012-2017)
Table Top Players of Metformin Oral hypoglycemic agents and insulin analogues Products List
Figure Global Metformin Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)
Table Top Players of Buformin Oral hypoglycemic agents and insulin analogues Products List
Figure Global Buformin Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)
Table Top Players of Phenformin Oral hypoglycemic agents and insulin analogues Products List
Figure Global Phenformin Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)
Table Top Players of Pioglitazone Oral hypoglycemic agents and insulin analogues Products List
Figure Global Pioglitazone Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)
Table Top Players of Rosiglitazone Oral hypoglycemic agents and insulin analogues Products List
Figure Global Rosiglitazone Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)
Table Global Oral hypoglycemic agents and insulin analogues Sales () by Secretagogue (2012-2017)
Table Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Secretagogue (2012-2017)
Figure Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Secretagogue in 2016
Table Global Oral hypoglycemic agents and insulin analogues Revenue (Million USD) by Secretagogue (2012-2017)
Table Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Secretagogue (2012-2017)
Figure Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Secretagogue in 2016
Table Global Oral hypoglycemic agents and insulin analogues Price () by Secretagogue (2012-2017)
Table Top Players of Acetohexamide Oral hypoglycemic agents and insulin analogues Products List
Figure Global Acetohexamide Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)
Table Top Players of Carbutamide Oral hypoglycemic agents and insulin analogues Products List
Figure Global Carbutamide Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)
Table Top Players of Chlorpropamide Oral hypoglycemic agents and insulin analogues Products List
Figure Global Chlorpropamide Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)
Table Top Players of Metahexamide Oral hypoglycemic agents and insulin analogues Products List
Figure Global Metahexamide Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)
Table Top Players of Tolazamide Oral hypoglycemic agents and insulin analogues Products List
Figure Global Tolazamide Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)
Table Global Oral hypoglycemic agents and insulin analogues Sales () by Insulin class (2012-2017)
Table Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Insulin class (2012-2017)
Figure Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Insulin class in 2016
Table Global Oral hypoglycemic agents and insulin analogues Revenue (Million USD) by Insulin class (2012-2017)
Table Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Insulin class (2012-2017)
Figure Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Insulin class in 2016
Table Global Oral hypoglycemic agents and insulin analogues Price () by Insulin class (2012-2017)
Table Top Players of Insulin Lispro Oral hypoglycemic agents and insulin analogues Products List
Figure Global Insulin Lispro Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)
Table Top Players of Insulin aspart Oral hypoglycemic agents and insulin analogues Products List
Figure Global Insulin aspart Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)
Table Top Players of Glulisine Oral hypoglycemic agents and insulin analogues Products List
Figure Global Glulisine Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)
Table Top Players of insulin Oral hypoglycemic agents and insulin analogues Products List
Figure Global insulin Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)
Table Top Players of insulin glargine Oral hypoglycemic agents and insulin analogues Products List
Figure Global insulin glargine Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)
Table Global Oral hypoglycemic agents and insulin analogues Sales () by Others (2012-2017)
Table Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Others (2012-2017)
Figure Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Others in 2016
Table Global Oral hypoglycemic agents and insulin analogues Revenue (Million USD) by Others (2012-2017)
Table Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Others (2012-2017)
Figure Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Others in 2016
Table Global Oral hypoglycemic agents and insulin analogues Price () by Others (2012-2017)
Table Top Players of Acarbose Oral hypoglycemic agents and insulin analogues Products List
Figure Global Acarbose Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)
Table Top Players of Miglitol Oral hypoglycemic agents and insulin analogues Products List
Figure Global Miglitol Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)
Table Top Players of Voglibose Oral hypoglycemic agents and insulin analogues Products List
Figure Global Voglibose Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)
Table Top Players of Pramlintide Oral hypoglycemic agents and insulin analogues Products List
Figure Global Pramlintide Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)
Table Top Players of Benfluorex Oral hypoglycemic agents and insulin analogues Products List
Figure Global Benfluorex Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)
Table Global Oral hypoglycemic agents and insulin analogues Sales () by (2012-2017)
Table Global Oral hypoglycemic agents and insulin analogues Sales Market Share by (2012-2017)
Figure Global Oral hypoglycemic agents and insulin analogues Sales Market Share by in 2016
Table Global Oral hypoglycemic agents and insulin analogues Revenue (Million USD) by (2012-2017)
Table Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by (2012-2017)
Figure Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by in 2016
Table Global Oral hypoglycemic agents and insulin analogues Price () by (2012-2017)
Table ASTRAZENECA AB Company Details and Competitors
Table ASTRAZENECA AB Key Oral hypoglycemic agents and insulin analogues Models and Performance
Table ASTRAZENECA AB Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast
Table ASTRAZENECA AB Oral hypoglycemic agents and insulin analogues Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure ASTRAZENECA AB Oral hypoglycemic agents and insulin analogues Sales(Million Unit) and Growth Rate (%)(2012-2017)
Figure ASTRAZENECA AB Oral hypoglycemic agents and insulin analogues Sales Market Share (%) in Global (2012-2017)
Figure ASTRAZENECA AB Oral hypoglycemic agents and insulin analogues Sales Revenue(Million USD) and Growth Rate (%)(2012-2017)
Figure ASTRAZENECA AB Oral hypoglycemic agents and insulin analogues Revenue Market Share (%) in Global (2012-2017)
Table AUROBINDO PHARMA LTD Company Details and Competitors
Table AUROBINDO PHARMA LTD Key Oral hypoglycemic agents and insulin analogues Models and Performance
Table AUROBINDO PHARMA LTD Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast
Table AUROBINDO PHARMA LTD Oral hypoglycemic agents and insulin analogues Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure AUROBINDO PHARMA LTD Oral hypoglycemic agents and insulin analogues Sales(Million Unit) and Growth Rate (%)(2012-2017)
Figure AUROBINDO PHARMA LTD Oral hypoglycemic agents and insulin analogues Sales Market Share (%) in Global (2012-2017)
Figure AUROBINDO PHARMA LTD Oral hypoglycemic agents and insulin analogues Sales Revenue(Million USD) and Growth Rate (%)(2012-2017)
Figure AUROBINDO PHARMA LTD Oral hypoglycemic agents and insulin analogues Revenue Market Share (%) in Global (2012-2017)
Table BAYER HLTHCARE Company Details and Competitors
Table BAYER HLTHCARE Key Oral hypoglycemic agents and insulin analogues Models and Performance
Table BAYER HLTHCARE Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast
Table BAYER HLTHCARE Oral hypoglycemic agents and insulin analogues Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure BAYER HLTHCARE Oral hypoglycemic agents and insulin analogues Sales(Million Unit) and Growth Rate (%)(2012-2017)
Figure BAYER HLTHCARE Oral hypoglycemic agents and insulin analogues Sales Market Share (%) in Global (2012-2017)
Figure BAYER HLTHCARE Oral hypoglycemic agents and insulin analogues Sales Revenue(Million USD) and Growth Rate (%)(2012-2017)
Figure BAYER HLTHCARE Oral hypoglycemic agents and insulin analogues Revenue Market Share (%) in Global (2012-2017)
Table BOEHRINGER INGELHEIM Company Details and Competitors
Table BOEHRINGER INGELHEIM Key Oral hypoglycemic agents and insulin analogues Models and Performance
Table BOEHRINGER INGELHEIM Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast
Table BOEHRINGER INGELHEIM Oral hypoglycemic agents and insulin analogues Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure BOEHRINGER INGELHEIM Oral hypoglycemic agents and insulin analogues Sales(Million Unit) and Growth Rate (%)(2012-2017)
Figure BOEHRINGER INGELHEIM Oral hypoglycemic agents and insulin analogues Sales Market Share (%) in Global (2012-2017)
Figure BOEHRINGER INGELHEIM Oral hypoglycemic agents and insulin analogues Sales Revenue(Million USD) and Growth Rate (%)(2012-2017)
Figure BOEHRINGER INGELHEIM Oral hypoglycemic agents and insulin analogues Revenue Market Share (%) in Global (2012-2017)
Table CIPLA LTD Company Details and Competitors
Table CIPLA LTD Key Oral hypoglycemic agents and insulin analogues Models and Performance
Table CIPLA LTD Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast
Table CIPLA LTD Oral hypoglycemic agents and insulin analogues Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure CIPLA LTD Oral hypoglycemic agents and insulin analogues Sales(Million Unit) and Growth Rate (%)(2012-2017)
Figure CIPLA LTD Oral hypoglycemic agents and insulin analogues Sales Market Share (%) in Global (2012-2017)
Figure CIPLA LTD Oral hypoglycemic agents and insulin analogues Sales Revenue(Million USD) and Growth Rate (%)(2012-2017)
Figure CIPLA LTD Oral hypoglycemic agents and insulin analogues Revenue Market Share (%) in Global (2012-2017)
Table DR REDDYS LABS LTD Company Details and Competitors
Table DR REDDYS LABS LTD Key Oral hypoglycemic agents and insulin analogues Models and Performance
Table DR REDDYS LABS LTD Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast
Table DR REDDYS LABS LTD Oral hypoglycemic agents and insulin analogues Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure DR REDDYS LABS LTD Oral hypoglycemic agents and insulin analogues Sales(Million Unit) and Growth Rate (%)(2012-2017)
Figure DR REDDYS LABS LTD Oral hypoglycemic agents and insulin analogues Sales Market Share (%) in Global (2012-2017)
Figure DR REDDYS LABS LTD Oral hypoglycemic agents and insulin analogues Sales Revenue(Million USD) and Growth Rate (%)(2012-2017)
Figure DR REDDYS LABS LTD Oral hypoglycemic agents and insulin analogues Revenue Market Share (%) in Global (2012-2017)
Table EPIC PHARMA LLC Company Details and Competitors
Table EPIC PHARMA LLC Key Oral hypoglycemic agents and insulin analogues Models and Performance
Table EPIC PHARMA LLC Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast
Table EPIC PHARMA LLC Oral hypoglycemic agents and insulin analogues Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure EPIC PHARMA LLC Oral hypoglycemic agents and insulin analogues Sales(Million Unit) and Growth Rate (%)(2012-2017)
Figure EPIC PHARMA LLC Oral hypoglycemic agents and insulin analogues Sales Market Share (%) in Global (2012-2017)
Figure EPIC PHARMA LLC Oral hypoglycemic agents and insulin analogues Sales Revenue(Million USD) and Growth Rate (%)(2012-2017)
Figure EPIC PHARMA LLC Oral hypoglycemic agents and insulin analogues Revenue Market Share (%) in Global (2012-2017)
Table HERITAGE PHARMS INC Company Details and Competitors
Table HERITAGE PHARMS INC Key Oral hypoglycemic agents and insulin analogues Models and Performance
Table HERITAGE PHARMS INC Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast
Table HERITAGE PHARMS INC Oral hypoglycemic agents and insulin analogues Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure HERITAGE PHARMS INC Oral hypoglycemic agents and insulin analogues Sales(Million Unit) and Growth Rate (%)(2012-2017)
Figure HERITAGE PHARMS INC Oral hypoglycemic agents and insulin analogues Sales Market Share (%) in Global (2012-2017)
Figure HERITAGE PHARMS INC Oral hypoglycemic agents and insulin analogues Sales Revenue(Million USD) and Growth Rate (%)(2012-2017)
Figure HERITAGE PHARMS INC Oral hypoglycemic agents and insulin analogues Revenue Market Share (%) in Global (2012-2017)
Table IMPAX LABS Company Details and Competitors
Table IMPAX LABS Key Oral hypoglycemic agents and insulin analogues Models and Performance
Table IMPAX LABS Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast
Table IMPAX LABS Oral hypoglycemic agents and insulin analogues Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure IMPAX LABS Oral hypoglycemic agents and insulin analogues Sales(Million Unit) and Growth Rate (%)(2012-2017)
Figure IMPAX LABS Oral hypoglycemic agents and insulin analogues Sales Market Share (%) in Global (2012-2017)
Figure IMPAX LABS Oral hypoglycemic agents and insulin analogues Sales Revenue(Million USD) and Growth Rate (%)(2012-2017)
Figure IMPAX LABS Oral hypoglycemic agents and insulin analogues Revenue Market Share (%) in Global (2012-2017)
Table INVAGEN PHARMS Company Details and Competitors
Table INVAGEN PHARMS Key Oral hypoglycemic agents and insulin analogues Models and Performance
Table INVAGEN PHARMS Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast
Table INVAGEN PHARMS Oral hypoglycemic agents and insulin analogues Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure INVAGEN PHARMS Oral hypoglycemic agents and insulin analogues Sales(Million Unit) and Growth Rate (%)(2012-2017)
Figure INVAGEN PHARMS Oral hypoglycemic agents and insulin analogues Sales Market Share (%) in Global (2012-2017)
Figure INVAGEN PHARMS Oral hypoglycemic agents and insulin analogues Sales Revenue(Million USD) and Growth Rate (%)(2012-2017)
Figure INVAGEN PHARMS Oral hypoglycemic agents and insulin analogues Revenue Market Share (%) in Global (2012-2017)
Table JANSSEN PHARMS Company Details and Competitors
Table LABS LLC Company Details and Competitors
Table LUPIN LTD Company Details and Competitors
Table MACLEODS PHARMS LTD Company Details and Competitors
Table MANNKIND Company Details and Competitors
Table MERCK SHARP DOHME Company Details and Competitors
Table MICRO LABS LTD INDIA Company Details and Competitors
Table MYLAN Company Details and Competitors
Table NOVO NORDISK INC Company Details and Competitors
Table PADDOCK LLC Company Details and Competitors
Table PAR PHARM Company Details and Competitors
Table PFIZER Company Details and Competitors
Table SANDOZ Company Details and Competitors
Table SANOFI AVENTIS US Company Details and Competitors
Table SANTARUS INC Company Details and Competitors
Table SB PHARMCO Company Details and Competitors
Table SUN PHARM INDS INC Company Details and Competitors
Table TAKEDA PHARMS USA Company Details and Competitors
Table TEVA Company Details and Competitors
Table APOTEX Company Details and Competitors
Table Global Oral hypoglycemic agents and insulin analogues Sales () by Appliance (2012-2017)
Figure Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Appliance (2012-2017)
Figure Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Appliance in 2016
Figure Global Department of endocrinology Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)
Figure Global Diabetes division Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)
Figure Global Pharmacy Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)
Figure Global Hospital Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)
Figure Global Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (%) Forecast (2017-2022)
Figure Global Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure Global Oral hypoglycemic agents and insulin analogues Price () Trend Forecast (2017-2022)
Table Global Oral hypoglycemic agents and insulin analogues Sales () Forecast by Regions (2017-2022)
Table Global Oral hypoglycemic agents and insulin analogues Sales Volume Share Forecast by Regions (2017-2022)
Figure Global Oral hypoglycemic agents and insulin analogues Sales Volume Share Forecast by Regions (2017-2022)
Figure Global Oral hypoglycemic agents and insulin analogues Sales Volume Share Forecast by Regions in 2022
Table Global Oral hypoglycemic agents and insulin analogues Sales () Forecast by Application (2017-2022)
Figure Global Oral hypoglycemic agents and insulin analogues Sales Volume Market Share Forecast by Application (2017-2022)
Figure Global Oral hypoglycemic agents and insulin analogues Sales Volume Market Share Forecast by Application in 2022
Table Global Oral hypoglycemic agents and insulin analogues Sales () Forecast by Insulin sensitizing agents (2017-2022)
Figure Global Oral hypoglycemic agents and insulin analogues Sales () Forecast by Insulin sensitizing agents (2017-2022)
Figure Global Oral hypoglycemic agents and insulin analogues Sales Volume Market Share Forecast by Insulin sensitizing agents in 2022
Table Global Oral hypoglycemic agents and insulin analogues Sales () Forecast by Secretagogue (2017-2022)
Figure Global Oral hypoglycemic agents and insulin analogues Sales () Forecast by Secretagogue (2017-2022)
Figure Global Oral hypoglycemic agents and insulin analogues Sales Volume Market Share Forecast by Secretagogue in 2022
Table Global Oral hypoglycemic agents and insulin analogues Sales () Forecast by Insulin class (2017-2022)
Figure Global Oral hypoglycemic agents and insulin analogues Sales () Forecast by Insulin class (2017-2022)
Figure Global Oral hypoglycemic agents and insulin analogues Sales Volume Market Share Forecast by Insulin class in 2022
Table Global Oral hypoglycemic agents and insulin analogues Sales () Forecast by Others (2017-2022)
Figure Global Oral hypoglycemic agents and insulin analogues Sales () Forecast by Others (2017-2022)
Figure Global Oral hypoglycemic agents and insulin analogues Sales Volume Market Share Forecast by Others in 2022